Abstract
A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have